Early trial tests new leukemia treatment approach in japan
NCT ID NCT06649006
Summary
This small, early-stage study tested the safety and side effects of an intravenous drug called blinatumomab in six Japanese adults with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL). Participants had already achieved remission with initial chemotherapy and received blinatumomab to help control the disease further. The main goal was to understand how the body processes the drug and what side effects might occur.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Akita University Hospital
Akita, Akita, 010-8543, Japan
-
Fukushima Medical University Hospital
Fukushima, Fukushima, 960-1295, Japan
-
Kanazawa University Hospital
Kanazawa, Ishikawa-ken, 920-8641, Japan
-
Kurume University Hospital
Kurume-shi, Fukuoka, 830-0011, Japan
-
Kyushu University Hospital
Fukuoka, Fukuoka, 812-8582, Japan
-
Yamagata University Hospital
Yamagata, Yamagata, 990-9585, Japan
Conditions
Explore the condition pages connected to this study.